open access

Vol 12, No 2 (2017)
Original Papers
Published online: 2017-04-20
Get Citation

The effect of atorvastatin in treatment of middle-age patients with advanced idiopathic dilated cardiomyopathy – a randomized prospective single centre study.

Tomasz Wcisło, Jarosław D. Kasprzak, Jarosław Drożdż
DOI: 10.5603/FC.2017.0022
·
Folia Cardiologica 2017;12(2):143-153.

open access

Vol 12, No 2 (2017)
Original Papers
Published online: 2017-04-20

Abstract

Introduction. Idiopathic dilated cardiomyopathy is a disease of unknown aetiology, characterized by left ventricular systolic dysfunction. Despite new diagnostic methods and pharmacological treatment, dilated cardiomyopathy still remains a major cause of morbidity and mortality. The aim of the study was to determine prognostic factors, efficacy of statin use, and clinical adverse events in patients with idiopathic dilated cardiomyopathy.

Material and methods. Ninety-five patients with idiopathic dilated cardiomyopathy (47 in the treated group and 48 in the control group) were randomized to receive add-on therapy with atorvastatin 20 mg daily. All patients underwent thorough clinical, electrocardiographic and echocardiographic evaluation at baseline and after 12 months of follow-up.

Results. During the 12 months of follow-up, 23 patients died (12 in the treated group and 11 in the control group). During the follow-up, the severity of heart failure symptoms (as measured by the NYHA functional class) decreased and the glomerular filtration rate increased in parallel to an improvement seen in several echocardiographic parameters.

Conclusions. Based on our study findings, statin use is not associated with a better prognosis in patients with idiopathic dilated cardiomyopathy. Risk stratification in this group of patients is possible on the basis of clinical, biochemical, and echocardiographic parameters.

Abstract

Introduction. Idiopathic dilated cardiomyopathy is a disease of unknown aetiology, characterized by left ventricular systolic dysfunction. Despite new diagnostic methods and pharmacological treatment, dilated cardiomyopathy still remains a major cause of morbidity and mortality. The aim of the study was to determine prognostic factors, efficacy of statin use, and clinical adverse events in patients with idiopathic dilated cardiomyopathy.

Material and methods. Ninety-five patients with idiopathic dilated cardiomyopathy (47 in the treated group and 48 in the control group) were randomized to receive add-on therapy with atorvastatin 20 mg daily. All patients underwent thorough clinical, electrocardiographic and echocardiographic evaluation at baseline and after 12 months of follow-up.

Results. During the 12 months of follow-up, 23 patients died (12 in the treated group and 11 in the control group). During the follow-up, the severity of heart failure symptoms (as measured by the NYHA functional class) decreased and the glomerular filtration rate increased in parallel to an improvement seen in several echocardiographic parameters.

Conclusions. Based on our study findings, statin use is not associated with a better prognosis in patients with idiopathic dilated cardiomyopathy. Risk stratification in this group of patients is possible on the basis of clinical, biochemical, and echocardiographic parameters.

Get Citation

Keywords

dilated cardiomyopathy, heart failure, New York Heart Association functional class, atorvastatin, echocardiography

About this article
Title

The effect of atorvastatin in treatment of middle-age patients with advanced idiopathic dilated cardiomyopathy – a randomized prospective single centre study.

Journal

Folia Cardiologica

Issue

Vol 12, No 2 (2017)

Pages

143-153

Published online

2017-04-20

DOI

10.5603/FC.2017.0022

Bibliographic record

Folia Cardiologica 2017;12(2):143-153.

Keywords

dilated cardiomyopathy
heart failure
New York Heart Association functional class
atorvastatin
echocardiography

Authors

Tomasz Wcisło
Jarosław D. Kasprzak
Jarosław Drożdż

References (35)
  1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circ. Circulation. 2013; 128(16): e240–e327.
  2. NICE. Chronic heart failure. National Clinical Guidelines for Diagnosis and Management in Primary and Secondary Care. The National Collaborating Centre for Chronic Conditions. NICE, London 2005: 1–163.
  3. Liu M, Wang F, Wang Y, et al. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther. 2009; 23(5): 369–376.
  4. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001; 22(3): 228–236.
  5. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29(2): 270–276.
  6. Cowie MR, Fox KF, Wood DA, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999; 20(6): 421–428.
  7. Maron BJ, Towbin JA, Thiene G, et al. American Heart Association, Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113(14): 1807–1816.
  8. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997; 350(9081): 829–833.
  9. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8): 977–982.
  10. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347(18): 1397–1402.
  11. Grünig E, Tasman JA, Kücherer H, et al. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 1998; 31(1): 186–194.
  12. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992; 326(2): 77–82.
  13. Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Little, Brown & Co, Boston 1994: 253–256.
  14. McMurray JV, Adamopoulos S, Anker SD. Wytyczne ESC dotyczące rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca na 2012 rok. Kardiol Pol. 2012; 70(supl. II): 101–176.
  15. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002; 105(7): 868–873.
  16. Gürgün C, Ildizli M, Yavuzgil O, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol. 2008; 123(2): 102–107.
  17. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004; 43(4): 642–648.
  18. Sola S, Mir MQS, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47(2): 332–337.
  19. Emberson JR, Ng LL, Armitage J, et al. Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol. 2007; 49(3): 311–319.
  20. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003; 108(7): 839–843.
  21. Ashton E, Liew D, Krum H. Should patients with chronic heart failure be treated with "statins"? Heart Fail Monit. 2003; 3(3): 82–86.
  22. Laufs U, Wassmann S, Schackmann S, et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol. 2004; 93(2): 103–108.
  23. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004; 93(9): 1124–1129.
  24. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357(22): 2248–2261.
  25. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716): 735–742.
  26. Bielecka-Dąbrowa A. Statyny a kardiomiopatia rozstrzeniowa. Pol Przeglad Kardiol. 2008; 10(2): 150–154.
  27. Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, et al. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up. Lipids Health Dis. 2013; 12: 47.
  28. Tsutamoto T, Sakai H, Ibe K, et al. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J. 2011; 75(9): 2160–2166.
  29. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009; 15(12): MS12–MS23.
  30. Cleland JGF, McMurray JJV, Kjekshus J, et al. CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009; 54(20): 1850–1859.
  31. McMurray JJV, Kjekshus J, Gullestad L, et al. CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009; 120(22): 2188–2196.
  32. Gullestad L, Ueland T, Kjekshus J, et al. CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012; 33(18): 2290–2296.
  33. Jennifer K, et al. Rogers, Pardeep S. Jhund, Ana-Cristina Perez, Effect of Rosuvastatin on Repeat Heart Failure HospitalizationsThe CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)CME. JCHF. 2014; 2(3): 289–297.
  34. Ghio S, Scelsi L, Latini R, et al. GISSI-HF investigators. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010; 12(12): 1345–1353.
  35. Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9645): 1231–1239.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl